These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11924112)

  • 1. Tyrosinaemia type II: an easily diagnosed metabolic disorder with a rewarding therapeutic response.
    al-Essa MA; Rashed MS; Ozand PT
    East Mediterr Health J; 1999 Nov; 5(6):1204-7. PubMed ID: 11924112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oculocutaneous tyrosinaemia or tyrosinaemia type 2: a case report.
    Valikhani M; Akhyani M; Jafari AK; Barzegari M; Toosi S
    J Eur Acad Dermatol Venereol; 2006 May; 20(5):591-4. PubMed ID: 16684290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diurnal variation of phenylalanine concentrations in tyrosinaemia type 1: should we be concerned?
    Daly A; Gokmen-Ozel H; MacDonald A; Preece MA; Davies P; Chakrapani A; McKiernan P
    J Hum Nutr Diet; 2012 Apr; 25(2):111-6. PubMed ID: 22168396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The genetic tyrosinemias.
    Scott CR
    Am J Med Genet C Semin Med Genet; 2006 May; 142C(2):121-6. PubMed ID: 16602095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Richner-Hanhart syndrome detected by expanded newborn screening.
    Meissner T; Betz RC; Pasternack SM; Eigelshoven S; Ruzicka T; Kruse R; Laitenberger G; Mayatepek E
    Pediatr Dermatol; 2008; 25(3):378-80. PubMed ID: 18577048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diagnostic error of mental retardation of neurometabolic origin confirmed by mass sequential spectrometry].
    Osorio-Orozco JH; Pourfarzam M
    Rev Neurol; 2000 Apr 16-30; 30(8):728-30. PubMed ID: 10893736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Richner-Hanhart syndrome (tyrosinemia II): early diagnosis of an incomplete presentation with unusual findings.
    Viglizzo GM; Occella C; Bleidl D; Rongioletti F
    Pediatr Dermatol; 2006; 23(3):259-61. PubMed ID: 16780475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A rapid ultra performance liquid chromatography tandem mass spectrometric method for measuring amino acids associated with maple syrup urine disease, tyrosinaemia and phenylketonuria.
    Freeto S; Mason D; Chen J; Scott RH; Narayan SB; Bennett MJ
    Ann Clin Biochem; 2007 Sep; 44(Pt 5):474-81. PubMed ID: 17761035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatorenal Tyrosinaemia: Impact of a Simplified Diet on Metabolic Control and Clinical Outcome.
    Bärhold F; Meyer U; Neugebauer AK; Thimm EM; Lier D; Rosenbaum-Fabian S; Och U; Fekete A; Möslinger D; Rohde C; Beblo S; Hochuli M; Bogovic N; Korpel V; Dahl SV; Mayorandan S; Fischer A; Freisinger P; Dokoupil K; Heddrich-Ellerbrok M; Jörg-Streller M; van Teeffelen-Heithoff A; Lahl J; Das AM
    Nutrients; 2020 Dec; 13(1):. PubMed ID: 33396520
    [No Abstract]   [Full Text] [Related]  

  • 10. Richner-Hanhart syndrome (tyrosinemia type II): a case report of delayed diagnosis with pseudodendritic corneal lesion.
    Iskeleli G; Bilgeç MD; Arici C; Atalay E; Oğreden T; Aydin A
    Turk J Pediatr; 2011; 53(6):692-4. PubMed ID: 22389994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behavioral and intellectual functioning in patients with tyrosinemia type I.
    Pohorecka M; Biernacka M; Jakubowska-Winecka A; Biernacki M; Kuśmierska K; Kowalik A; Sykut-Cegielska J
    Pediatr Endocrinol Diabetes Metab; 2012; 18(3):96-100. PubMed ID: 23146787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tyrosinemia type II. Case report].
    Benatiya AI; Bouayed MA; Touiza E; Daoudi K; Bhalil S; Elmesbahi I; Tahri H
    Bull Soc Belge Ophtalmol; 2005; (296):57-61. PubMed ID: 16050420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural Protein Tolerance and Metabolic Control in Patients with Hereditary Tyrosinaemia Type 1.
    Yilmaz O; Daly A; Pinto A; Ashmore C; Evans S; Gupte G; Santra S; Preece MA; Mckiernan P; Kitchen S; Ayhan NY; MacDonald A
    Nutrients; 2020 Apr; 12(4):. PubMed ID: 32325917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenylalanine supplementation improves the phenylalanine profile in tyrosinaemia.
    Wilson CJ; Van Wyk KG; Leonard JV; Clayton PT
    J Inherit Metab Dis; 2000 Nov; 23(7):677-83. PubMed ID: 11117429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuropsychological outcome of NTBC-treated patients with tyrosinaemia type 1.
    De Laet C; Munoz VT; Jaeken J; François B; Carton D; Sokal EM; Dan B; Goyens PJ
    Dev Med Child Neurol; 2011 Oct; 53(10):962-4. PubMed ID: 21745202
    [No Abstract]   [Full Text] [Related]  

  • 16. The history of hypertyrosinemia caused by high protein diets.
    Menkes JH
    J Pediatr; 2006 Feb; 148(2):283-4. PubMed ID: 16492447
    [No Abstract]   [Full Text] [Related]  

  • 17. The inclusion of succinylacetone as marker for tyrosinemia type I in expanded newborn screening programs.
    la Marca G; Malvagia S; Pasquini E; Innocenti M; Fernandez MR; Donati MA; Zammarchi E
    Rapid Commun Mass Spectrom; 2008; 22(6):812-8. PubMed ID: 18278819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosinaemia type II with diffuse plantar keratoderma and self-mutilation.
    Madan V; Gupta U
    Clin Exp Dermatol; 2006 Jan; 31(1):54-6. PubMed ID: 16309482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of tyrosinaemia type III.
    Ellaway CJ; Holme E; Standing S; Preece MA; Green A; Ploechl E; Ugarte M; Trefz FK; Leonard JV
    J Inherit Metab Dis; 2001 Dec; 24(8):824-32. PubMed ID: 11916315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolated corneal pseudodendrites as the initial manifestation of tyrosinemia type II in monozygotic twins.
    Kymionis GD; Kankariya VP; Kontadakis GA; Ziakas NG
    J Pediatr Ophthalmol Strabismus; 2012 May; 49 Online():e33-6. PubMed ID: 22588828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.